Venclexta

Venclexta (venetoclax) is a targeted oral cancer therapy co-developed by AbbVie and Genentech (Roche). It belongs to a class called BCL-2 inhibitors — the first drugs that work by blocking BCL-2, a protein that prevents cancer cells from self-destructing, restoring the cell's natural ability to undergo programmed cell death.

Without insurance, Venclexta can cost $20,000–$25,000 per month — one of the most expensive oral cancer medications available. Because it is co-marketed by two manufacturers, patients may have access to assistance programs from both AbbVie and Genentech.

How to Afford Venclexta

• Uninsured patients may receive free Venclexta through myAbbVie Assist (AbbVie's PAP) or Genentech Access Solutions (Genentech's PAP), or both.
• Commercially insured patients can reduce copay costs through the Venclexta Savings Card.
• Medicare patients facing catastrophic drug costs may qualify for the Extra Help program (LIS).

ClariMeds evaluates eligibility for both manufacturers' programs simultaneously and applies to the most beneficial one on your behalf.

What Does Venclexta Treat?

Venclexta is FDA-approved for:

• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) — as a first-line treatment (combined with obinutuzumab) or after at least one prior therapy (combined with rituximab or as monotherapy)
• Acute myeloid leukemia (AML) — in combination with azacitidine, decitabine, or low-dose cytarabine, for newly diagnosed adults 75 and older or who have comorbidities that prevent intensive chemotherapy

How Venclexta Works

BCL-2 is an anti-apoptotic protein that many cancer cells overexpress to survive — it blocks the cell's internal "self-destruct" signals. Venetoclax is a selective, potent BCL-2 inhibitor that binds directly to the BCL-2 protein and prevents it from blocking apoptosis (programmed cell death). This restores the cancer cell's ability to self-destruct, causing rapid tumor cell death — a mechanism called "direct tumor lysis." Because venetoclax works through a fundamentally different pathway than traditional chemotherapy, it can be effective even in patients whose cancer has become resistant to prior treatments.